Antiproteinuric effect of olmesartan in patients with IgA nephropathy
IgA nephropathy is one of the most common primary glomerulonephritides, and the clinical course of almost 40% of the patients progresses to end-stage renal disease (ESRD) within 20 years. Angiotensin-converting enzyme (ACE) inhibitors and/ or angiotensin II receptor blockers (ARBs) induce a marked r...
Gespeichert in:
| Veröffentlicht in: | Journal of nephrology 2009-03, Vol.22 (2), p.224-231 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 231 |
|---|---|
| container_issue | 2 |
| container_start_page | 224 |
| container_title | Journal of nephrology |
| container_volume | 22 |
| creator | Tomino, Yasuhiko Kawamura, Tetsuya Kimura, Kenjiro Endoh, Masayuki Hosoya, Tatsuo Horikoshi, Satoshi Utsunomiya, Yasunori Yasuda, Takashi Toyoda, Masao Tsuge, Toshinao Kaneko, Kotaro |
| description | IgA nephropathy is one of the most common primary glomerulonephritides, and the clinical course of almost 40% of the patients progresses to end-stage renal disease (ESRD) within 20 years. Angiotensin-converting enzyme (ACE) inhibitors and/ or angiotensin II receptor blockers (ARBs) induce a marked renoprotective effect in nondiabetic chronic proteinuric nephropathies including IgA nephropathy. However, in Japan, ACE inhibitors and ARBs are not used for normotensive patients. The purpose of the present study was to evaluate the antiproteinuric effect of olmesartan, one of the ARBs, in normotensive patients with IgA nephropathy in Japan.
Olmesartan was given to 25 patients for 16 weeks. The initial dose was 5 mg and was increased stepwise to 10 mg, 20 mg and 40 mg.
Final doses were 40 mg (n=11), 20 mg (n=5), 10 mg (n=7) and 5 mg (n=2). The change in urinary protein to creatinine ratio was -56.2%+/-22.8% at week 16. Creatinine clearance showed no changes throughout the study period. Blood pressure (systolic/diastolic) was 118.9+/-7.0 / 76.8+/-7.4 mm Hg in the lead-in period and decreased to 107.0+/-10.1/66.3+/-7.8 mm Hg at week 16. At the end of treatment with olmesartan, no correlation was observed between changes in the urinary protein to creatinine ratio and mean blood pressure based on investigation of dispersion diagrams.
Olmesartan monotherapy showed robust reduction of urinary protein in normotensive IgA nephropathy patients, suggesting that this effect is independent of its blood pressure-lowering properties. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_67147468</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67147468</sourcerecordid><originalsourceid>FETCH-LOGICAL-p209t-e97dfb0b97a70feadf7b882b86ef5fa3f218302dce833ced1ed1f0fe308c7be3</originalsourceid><addsrcrecordid>eNo1j01LxDAYhHNQ3HX1L0hO3gr5apMey7LqwsJe9l6S9I2NtGlNUmT_vQVXGBgYHoaZO7SllNFCCaY26DGlL0JYWTLxgDa05kooQbbo0ITs5zhl8GGJ3mJwDmzGk8PTMELSMeuAfcCzzh5CTvjH5x4fPxscYO7jtOb99QndOz0keL75Dl3eDpf9R3E6vx_3zamYGalzAbXsnCGmlloSB7pz0ijFjKrAlU5zx6jihHUWFOcWOrrKrSAnykoDfIde_2rXwd8LpNyOPlkYBh1gWlJbSSqkqNQKvtzAxYzQtXP0o47X9v83_wU_BlU0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67147468</pqid></control><display><type>article</type><title>Antiproteinuric effect of olmesartan in patients with IgA nephropathy</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Tomino, Yasuhiko ; Kawamura, Tetsuya ; Kimura, Kenjiro ; Endoh, Masayuki ; Hosoya, Tatsuo ; Horikoshi, Satoshi ; Utsunomiya, Yasunori ; Yasuda, Takashi ; Toyoda, Masao ; Tsuge, Toshinao ; Kaneko, Kotaro</creator><creatorcontrib>Tomino, Yasuhiko ; Kawamura, Tetsuya ; Kimura, Kenjiro ; Endoh, Masayuki ; Hosoya, Tatsuo ; Horikoshi, Satoshi ; Utsunomiya, Yasunori ; Yasuda, Takashi ; Toyoda, Masao ; Tsuge, Toshinao ; Kaneko, Kotaro</creatorcontrib><description>IgA nephropathy is one of the most common primary glomerulonephritides, and the clinical course of almost 40% of the patients progresses to end-stage renal disease (ESRD) within 20 years. Angiotensin-converting enzyme (ACE) inhibitors and/ or angiotensin II receptor blockers (ARBs) induce a marked renoprotective effect in nondiabetic chronic proteinuric nephropathies including IgA nephropathy. However, in Japan, ACE inhibitors and ARBs are not used for normotensive patients. The purpose of the present study was to evaluate the antiproteinuric effect of olmesartan, one of the ARBs, in normotensive patients with IgA nephropathy in Japan.
Olmesartan was given to 25 patients for 16 weeks. The initial dose was 5 mg and was increased stepwise to 10 mg, 20 mg and 40 mg.
Final doses were 40 mg (n=11), 20 mg (n=5), 10 mg (n=7) and 5 mg (n=2). The change in urinary protein to creatinine ratio was -56.2%+/-22.8% at week 16. Creatinine clearance showed no changes throughout the study period. Blood pressure (systolic/diastolic) was 118.9+/-7.0 / 76.8+/-7.4 mm Hg in the lead-in period and decreased to 107.0+/-10.1/66.3+/-7.8 mm Hg at week 16. At the end of treatment with olmesartan, no correlation was observed between changes in the urinary protein to creatinine ratio and mean blood pressure based on investigation of dispersion diagrams.
Olmesartan monotherapy showed robust reduction of urinary protein in normotensive IgA nephropathy patients, suggesting that this effect is independent of its blood pressure-lowering properties.</description><identifier>ISSN: 1121-8428</identifier><identifier>PMID: 19384840</identifier><language>eng</language><publisher>Italy</publisher><subject>Administration, Oral ; Adult ; Angiotensin II Type 1 Receptor Blockers - administration & dosage ; Angiotensin II Type 1 Receptor Blockers - therapeutic use ; Blood Pressure - drug effects ; Dose-Response Relationship, Drug ; Female ; Follow-Up Studies ; Glomerulonephritis, IGA - complications ; Glomerulonephritis, IGA - drug therapy ; Glomerulonephritis, IGA - urine ; Humans ; Imidazoles - administration & dosage ; Imidazoles - therapeutic use ; Male ; Middle Aged ; Proteinuria - drug therapy ; Proteinuria - etiology ; Proteinuria - urine ; Tetrazoles - administration & dosage ; Tetrazoles - therapeutic use ; Treatment Outcome ; Urinalysis ; Young Adult</subject><ispartof>Journal of nephrology, 2009-03, Vol.22 (2), p.224-231</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19384840$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tomino, Yasuhiko</creatorcontrib><creatorcontrib>Kawamura, Tetsuya</creatorcontrib><creatorcontrib>Kimura, Kenjiro</creatorcontrib><creatorcontrib>Endoh, Masayuki</creatorcontrib><creatorcontrib>Hosoya, Tatsuo</creatorcontrib><creatorcontrib>Horikoshi, Satoshi</creatorcontrib><creatorcontrib>Utsunomiya, Yasunori</creatorcontrib><creatorcontrib>Yasuda, Takashi</creatorcontrib><creatorcontrib>Toyoda, Masao</creatorcontrib><creatorcontrib>Tsuge, Toshinao</creatorcontrib><creatorcontrib>Kaneko, Kotaro</creatorcontrib><title>Antiproteinuric effect of olmesartan in patients with IgA nephropathy</title><title>Journal of nephrology</title><addtitle>J Nephrol</addtitle><description>IgA nephropathy is one of the most common primary glomerulonephritides, and the clinical course of almost 40% of the patients progresses to end-stage renal disease (ESRD) within 20 years. Angiotensin-converting enzyme (ACE) inhibitors and/ or angiotensin II receptor blockers (ARBs) induce a marked renoprotective effect in nondiabetic chronic proteinuric nephropathies including IgA nephropathy. However, in Japan, ACE inhibitors and ARBs are not used for normotensive patients. The purpose of the present study was to evaluate the antiproteinuric effect of olmesartan, one of the ARBs, in normotensive patients with IgA nephropathy in Japan.
Olmesartan was given to 25 patients for 16 weeks. The initial dose was 5 mg and was increased stepwise to 10 mg, 20 mg and 40 mg.
Final doses were 40 mg (n=11), 20 mg (n=5), 10 mg (n=7) and 5 mg (n=2). The change in urinary protein to creatinine ratio was -56.2%+/-22.8% at week 16. Creatinine clearance showed no changes throughout the study period. Blood pressure (systolic/diastolic) was 118.9+/-7.0 / 76.8+/-7.4 mm Hg in the lead-in period and decreased to 107.0+/-10.1/66.3+/-7.8 mm Hg at week 16. At the end of treatment with olmesartan, no correlation was observed between changes in the urinary protein to creatinine ratio and mean blood pressure based on investigation of dispersion diagrams.
Olmesartan monotherapy showed robust reduction of urinary protein in normotensive IgA nephropathy patients, suggesting that this effect is independent of its blood pressure-lowering properties.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Angiotensin II Type 1 Receptor Blockers - administration & dosage</subject><subject>Angiotensin II Type 1 Receptor Blockers - therapeutic use</subject><subject>Blood Pressure - drug effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Glomerulonephritis, IGA - complications</subject><subject>Glomerulonephritis, IGA - drug therapy</subject><subject>Glomerulonephritis, IGA - urine</subject><subject>Humans</subject><subject>Imidazoles - administration & dosage</subject><subject>Imidazoles - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Proteinuria - drug therapy</subject><subject>Proteinuria - etiology</subject><subject>Proteinuria - urine</subject><subject>Tetrazoles - administration & dosage</subject><subject>Tetrazoles - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Urinalysis</subject><subject>Young Adult</subject><issn>1121-8428</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j01LxDAYhHNQ3HX1L0hO3gr5apMey7LqwsJe9l6S9I2NtGlNUmT_vQVXGBgYHoaZO7SllNFCCaY26DGlL0JYWTLxgDa05kooQbbo0ITs5zhl8GGJ3mJwDmzGk8PTMELSMeuAfcCzzh5CTvjH5x4fPxscYO7jtOb99QndOz0keL75Dl3eDpf9R3E6vx_3zamYGalzAbXsnCGmlloSB7pz0ijFjKrAlU5zx6jihHUWFOcWOrrKrSAnykoDfIde_2rXwd8LpNyOPlkYBh1gWlJbSSqkqNQKvtzAxYzQtXP0o47X9v83_wU_BlU0</recordid><startdate>20090301</startdate><enddate>20090301</enddate><creator>Tomino, Yasuhiko</creator><creator>Kawamura, Tetsuya</creator><creator>Kimura, Kenjiro</creator><creator>Endoh, Masayuki</creator><creator>Hosoya, Tatsuo</creator><creator>Horikoshi, Satoshi</creator><creator>Utsunomiya, Yasunori</creator><creator>Yasuda, Takashi</creator><creator>Toyoda, Masao</creator><creator>Tsuge, Toshinao</creator><creator>Kaneko, Kotaro</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20090301</creationdate><title>Antiproteinuric effect of olmesartan in patients with IgA nephropathy</title><author>Tomino, Yasuhiko ; Kawamura, Tetsuya ; Kimura, Kenjiro ; Endoh, Masayuki ; Hosoya, Tatsuo ; Horikoshi, Satoshi ; Utsunomiya, Yasunori ; Yasuda, Takashi ; Toyoda, Masao ; Tsuge, Toshinao ; Kaneko, Kotaro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p209t-e97dfb0b97a70feadf7b882b86ef5fa3f218302dce833ced1ed1f0fe308c7be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Angiotensin II Type 1 Receptor Blockers - administration & dosage</topic><topic>Angiotensin II Type 1 Receptor Blockers - therapeutic use</topic><topic>Blood Pressure - drug effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Glomerulonephritis, IGA - complications</topic><topic>Glomerulonephritis, IGA - drug therapy</topic><topic>Glomerulonephritis, IGA - urine</topic><topic>Humans</topic><topic>Imidazoles - administration & dosage</topic><topic>Imidazoles - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Proteinuria - drug therapy</topic><topic>Proteinuria - etiology</topic><topic>Proteinuria - urine</topic><topic>Tetrazoles - administration & dosage</topic><topic>Tetrazoles - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Urinalysis</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tomino, Yasuhiko</creatorcontrib><creatorcontrib>Kawamura, Tetsuya</creatorcontrib><creatorcontrib>Kimura, Kenjiro</creatorcontrib><creatorcontrib>Endoh, Masayuki</creatorcontrib><creatorcontrib>Hosoya, Tatsuo</creatorcontrib><creatorcontrib>Horikoshi, Satoshi</creatorcontrib><creatorcontrib>Utsunomiya, Yasunori</creatorcontrib><creatorcontrib>Yasuda, Takashi</creatorcontrib><creatorcontrib>Toyoda, Masao</creatorcontrib><creatorcontrib>Tsuge, Toshinao</creatorcontrib><creatorcontrib>Kaneko, Kotaro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tomino, Yasuhiko</au><au>Kawamura, Tetsuya</au><au>Kimura, Kenjiro</au><au>Endoh, Masayuki</au><au>Hosoya, Tatsuo</au><au>Horikoshi, Satoshi</au><au>Utsunomiya, Yasunori</au><au>Yasuda, Takashi</au><au>Toyoda, Masao</au><au>Tsuge, Toshinao</au><au>Kaneko, Kotaro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antiproteinuric effect of olmesartan in patients with IgA nephropathy</atitle><jtitle>Journal of nephrology</jtitle><addtitle>J Nephrol</addtitle><date>2009-03-01</date><risdate>2009</risdate><volume>22</volume><issue>2</issue><spage>224</spage><epage>231</epage><pages>224-231</pages><issn>1121-8428</issn><abstract>IgA nephropathy is one of the most common primary glomerulonephritides, and the clinical course of almost 40% of the patients progresses to end-stage renal disease (ESRD) within 20 years. Angiotensin-converting enzyme (ACE) inhibitors and/ or angiotensin II receptor blockers (ARBs) induce a marked renoprotective effect in nondiabetic chronic proteinuric nephropathies including IgA nephropathy. However, in Japan, ACE inhibitors and ARBs are not used for normotensive patients. The purpose of the present study was to evaluate the antiproteinuric effect of olmesartan, one of the ARBs, in normotensive patients with IgA nephropathy in Japan.
Olmesartan was given to 25 patients for 16 weeks. The initial dose was 5 mg and was increased stepwise to 10 mg, 20 mg and 40 mg.
Final doses were 40 mg (n=11), 20 mg (n=5), 10 mg (n=7) and 5 mg (n=2). The change in urinary protein to creatinine ratio was -56.2%+/-22.8% at week 16. Creatinine clearance showed no changes throughout the study period. Blood pressure (systolic/diastolic) was 118.9+/-7.0 / 76.8+/-7.4 mm Hg in the lead-in period and decreased to 107.0+/-10.1/66.3+/-7.8 mm Hg at week 16. At the end of treatment with olmesartan, no correlation was observed between changes in the urinary protein to creatinine ratio and mean blood pressure based on investigation of dispersion diagrams.
Olmesartan monotherapy showed robust reduction of urinary protein in normotensive IgA nephropathy patients, suggesting that this effect is independent of its blood pressure-lowering properties.</abstract><cop>Italy</cop><pmid>19384840</pmid><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1121-8428 |
| ispartof | Journal of nephrology, 2009-03, Vol.22 (2), p.224-231 |
| issn | 1121-8428 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67147468 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Administration, Oral Adult Angiotensin II Type 1 Receptor Blockers - administration & dosage Angiotensin II Type 1 Receptor Blockers - therapeutic use Blood Pressure - drug effects Dose-Response Relationship, Drug Female Follow-Up Studies Glomerulonephritis, IGA - complications Glomerulonephritis, IGA - drug therapy Glomerulonephritis, IGA - urine Humans Imidazoles - administration & dosage Imidazoles - therapeutic use Male Middle Aged Proteinuria - drug therapy Proteinuria - etiology Proteinuria - urine Tetrazoles - administration & dosage Tetrazoles - therapeutic use Treatment Outcome Urinalysis Young Adult |
| title | Antiproteinuric effect of olmesartan in patients with IgA nephropathy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T21%3A23%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antiproteinuric%20effect%20of%20olmesartan%20in%20patients%20with%20IgA%20nephropathy&rft.jtitle=Journal%20of%20nephrology&rft.au=Tomino,%20Yasuhiko&rft.date=2009-03-01&rft.volume=22&rft.issue=2&rft.spage=224&rft.epage=231&rft.pages=224-231&rft.issn=1121-8428&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E67147468%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67147468&rft_id=info:pmid/19384840&rfr_iscdi=true |